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Background/aim: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has been used for the treatment of various refractory
solid tumors during the last two decades. After the demonstration of graft-versus-leukemia (GvL) effect in a leukemic murine model
following allo-HSCT from other strains of mice, graft-versus-tumor (GvT) effect in a solid tumor after allo-HSCT has also been
reported in a murine model in 1984. Several trials have reported the presence of a GvT effect in patients with various refractory solid
tumors, including renal, ovarian and colon cancers, as well as soft tissue sarcomas [1]. The growing data on haploidentical transplants
also indicate GvT effect in some pediatric refractory solid tumors. Novel immunotherapy-based treatment modalities aim at inducing
an allo-reactivity against the metastatic solid tumor via a GvT effect. Recipient derived immune effector cells (RDICs) in the antitumor
reactivity following allo-HSCT have also been considered as an emerging therapy for advanced refractory solid tumors.
Conclusion: This review summarizes the background, rationale, and clinical results of immune-based strategies using GvT effect for the
treatment of various metastatic and refractory solid tumors, as well as innovative approaches such as haploidentical HSCT, CAR-T cell
therapies and tumor infiltrating lymphocytes (TIL).
Key words: Graft-versus-tumor effect, recipient derived immune effector cells, allogeneic hematopoietic stem cell transplantation, solid
tumors

1. Introduction
High dose chemotherapy with autologous hematopoietic
stem cell transplantation (HSCT) could not achieve the
expected treatment success in patients with solid tumors
[2–12]. The ongoing clinical need formore durable
responses hasled to the search of novel approaches
focusing on the graft-versus-tumor (GvT) effect via
allogeneic HSCT (allo-HSCT) with reduced intensity
conditioning (RIC) and haploidentical HSCT [1, 9–11,
13–18]. Allo-HSCT has been used for the treatment
of various refractory solid tumors during the last two
decades. GvT effect in a solid tumor after allo-HSCT
has also been reported in a murine model in 1984 after
the demonstration of graft-versus-leukemia (GvL) effect
in a leukemic murine model following allo-HSCT from
other strains of mice [19, 20]. Phase I and II trials using
allo-HSCT with RIC conducted by the European Society
for Blood and Marrow Transplantation Solid Tumors
Working Party (EMBT-STWP) have reported the presence
of a GvT effect in patients with various refractorysolid
tumors,including renal, ovarian and colon cancers,as

well as soft tissue sarcomas[1].The growing data on
haploidentical transplants also indicate GvT effect in some
pediatric refractory solid tumors [21–25].
The standard chemotherapy-based approaches have
been shifting towards immunotherapy-based modalities,
which aim at inducing an allo-reactivity against the
metastatic solid tumor via a GvT effect [13, 26–33]. The
acceptable toxicity profile has enabled allo-HSCT with
RIC to be an alternative for the elderly and medically
fragile patients with refractory metastatic solid tumors[13,
26].The evolving evidence has also indicated the potential
role of recipient derived immune effector cells (RDICs) in
the antitumor reactivity following allo-HSCT, which has
been considered as an emerging therapy for advanced
refractory solid tumors[1, 34].
This review summarizes the background, rationale,
and clinical results of immune-based strategies using
GvT effect for the treatment of various metastatic and
refractory solid tumors, as well as innovative approaches
such as haploidentical HSCT, CAR-T cell therapies and
tumor infiltrating lymphocytes (TIL).
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2. Cytotoxic adoptive T-cell therapy
Novel approaches including adoptive T-cell therapy
(ATCT), targeted therapies and allo-HSCT with RIC are
able to induce more durable responses via the advantage of
a GvT effect [1, 13]. Better understanding the mechanisms
behind the adoptive immune system has enabled the
establishment of new targets for the treatment of various
solid tumors [35]. The GvT effect and tumor response
after allo-HSCT with RIC depend on the activity and
interaction of RDICs, leukocyte-activated killer cells
(LAKs) and cytokine-induced killer cells (CIKs). Thus,
it may also be regarded as a nonspecific ATCT. ATCT
involves the expansion of cytotoxic immune effector
cells of either donor or recipient type [36]. According to
results of some early phase trials, ATCT may be a potent
immunotherapeutic approach in refractory solid tumors
[35]. There remains much more to be discovered regarding
the interactions of T-cell subsets, mechanisms of GvT
effect and differences between GvL effect of hematologic
malignancies and GvT effect in refractory solid tumors.
3. Graft-versus-tumor effect
Graft-versus-host disease (GvHD) and therefore GvL
effect occurring after allo-HSCT contributes to and
maintains an antileukemic feature [37, 38]. Chronic
GvHD generally leads to a more potent GvL effect than
acute GvHD [39]. The duration of remission is reported
to be higheramong patients with GvHD when compared
to ones without GvHD [40]. Indirect evidences for the
presence of an immune-mediated GvL effect include
the lower risk of relapse among patients undergoing
allo-HSCT when compared to autologous HSCT and an
increased risk of relapse among patients receiving T-cell
depleted transplants [41, 42]. The direct evidence of GvL
effect can be interpreted from the posttransplant studies
reporting an augmentation of GvL effect following donor
lymphocyte infusions (DLI) after allo-HSCT [43]. DLI
without cytotoxic therapyis associated with a high rate
and durability of remissionwhen used for the treatment of
relapse after allo-HSCT [44–46].
The activation of Fas-dependent killing and perforin
degranulationvia the GvL effect, which is mediated by
donor T-cells (CD4+, CD8+ and natural killer – NKcells), eradicates malignant cells [47, 48]. Interferon-C,
interleukin-2 and tumor necrosis factor-αare the main
cytokines that potentiate the GvL effect [49]. Posttransplant
ATCT against human cancer-associated antigens, T-cell
receptor genes or minor histocompatibility antigens (e.g.;
HA-1,HA-3, etc.) may also induce antitumor effects [50].
The development of acute and chronic GvHD after
allo-HSCT, which is an immuno-modulatory therapy
aiming at exploiting a GvT effect for solid tumors, has
been linked to a better response rate[1]. The identification
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of antigen targets of donor and RDICs and development of
targeted therapies may further increase the GvT effect of
allo-HSCT for solid tumorsandalso reduce the treatment
toxicity[1]. However, the critical balance between effective
immunosuppression, GvHD and relapse still remains as
amajor concern.
3.1. GvT effect in renal cell carcinoma
Although RCC is sensitive to immunotherapy, interferon-α
with or without interleukin-2 (IL-2) yields unsatisfactory
response (10%–20%) and long-term progression-free
survival (PFS) rates of 4%–15% [51–53].Although the
introduction of novel immunotherapeutic agents, such
as anti-PDL-1 antibodies (nivolumab and ipilimumab)
provided some improvement in overall survival rates of
RCC patients, none of the current drugs have a curative
potential in RCC [54].
Allo-HSCT with RIC has been considered as a
promising option on the basis of GvT effect in this setting
[27, 28, 55, 56]. The first series of allo-HSCT with RIC
reported a 53% response rate for cytokine-refractory
RCC[27].In the largest series of allo-HSCT with RIC in
RCC patients by the EBMT-STWP, in which a fludarabinebased conditioning was administered to all 124 patients,
TRM at the end of first year was 16% and mostly
associated with acute GvHD [56]. A complete response
was achieved in 4 patients at a median of 150 (42–600)
days posttransplant with an overall response rate of 22.5%.
Another trial with 75 metastatic RCC patients receiving
allo-HSCT with RIC reported a sustained engraftment in
74 out of 75 patients [57]. The frequency of chronic GvHD
was 50% and associated with a significant tumor response.
As a result, a reasonable GvT effect in RCC patients
receiving allo-HSCT with RIC was documented especially
in the presence of chronic GvHD, which led to an increase
in survival rates.
3.2. GvT effect in refractory and resistant colorectal cancer
The median survival in refractory and resistant colon
cancer still remains as low as 9 to 12 months after secondline treatment [58]. The addition of monoclonal antibodies,
such as cetuximab or bevacizumabto combination
chemotherapiesmay partially increase remission and
survival rates. However, durable remission usually
cannot be achieved, especially in the presence of resistant
disease [59, 60]. Allo-HSCT with RIC has been studied
as animmunotherapy-based therapeutic strategy for the
management of metastatic colorectal cancer (mCRC)
[15, 16, 61]. Hentsschke et al. reported 6 mCRC patients
receiving allo-HSCT with RIC, which yielded 1 complete
response and 1 mixed response [62]. In amulticenter trial
by EBMT, 39 patients with mCRC had allo-HSCT with RIC
and all patients engrafted (mediandonor T-cellchimerism
of 90% at day +60). Transplant-related morbidities were
limited. Grades II-IV acute GvHD occurred in 14 patients
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(35%) and chronic GvHD in 9 (23%). TRM occurred
in 4 patients (10%). The best tumor responses were: 1
complete response (CR) (2%), 7 partial response (PR) (18
%) and 10 stable disease (SD) (26%), leading to an over
all disease control in 18 of 39 patients (46%)[63,64]. The
exploitation of GvT effect with allo-HSCT in refractory
mCRC might be an alternative to conventional strategies
and may sometimesyield favorable outcomes, especially in
the presence of chronic GvHD, among young patients with
refractory mCRC.
3.3. GvT effect in refractory ovarian cancer
Bay et al. reported 5 refractory ovarian cancer (OC)
patients receiving allo-HSCT with RIC. Tumor regression
were observed in 4 patients during acute or chronic
GvHD and relapse occurred in 1 patient treated with
methylprednisolone for chronic GvHD [65]. EBMT-STWP
also evaluated 17 heavily pretreated refractory OC patients,
retrospectively. Mortality was reported in 11 patients, 8 of
whom died of tumor progression at a median follow-up
of 296 days (range 51–599) [66]. Grades 2–4 acute GvHD
was seen in 8 patients, 7 (41%) of whom had a partial
response. DLI was associated with a tumor regression in
1 out of 3 patients. These data support the presence of a
GvT effect associated with the severity of GvHD. Another
retrospective multicenter study including 30 OC patients
receiving allografts reported that the presence of chronic
GvHD was associated with a significantly higher overall
survival (OS) rate (17.6 months vs. 6.5 months, P < 0.05).
An objective response rate of 50% and TRM of 20% were
reported at the end of first year [67]. Median OS was 10.4
months with a median follow-up of 74.5 months (range
16–148 months).
3.4. GvT effect in breast cancer
Morecki et al. demonstrated a GvT effect in mice implanted
with 4T1 mammary carcinoma cell line and given minor
histocompatibility mismatched DBA/2 spleen cells [68].
This direct GvT effect mediated by the alloreactive donor
splenocytes in the absence of any anticarcinoma agents
has also been demonstrated by direct inhibition of liver
metastases through intraportal inoculation of allogeneic
splenocytes, but not syngeneic splenocytes [69].
The first report of allo-HSCT in metastatic breast
cancer (BC) was published by Eibl et al. in 1996 [13].
The advantages of allo-HSCT over autologous HSCT for
metastatic BC are i) cancer-free graft and ii) immunemediated GvT effects mediated by human leukocyte
antigen compatible donor T-cells [1, 33, 70].After the
demonstration of tumor regression in metastatic BC via
allogeneic T-cell mediated GvT effects in several murine
models [71, 72], a study by the National Cancer Institute
including 16 metastatic BC patients investigated whether
a clinical graft-versus-BC effect existed via allogeneic
lymphocytes after allo-HSCT from HLA-matched

siblings following a RIC regimen. In order to avoid the
overlap of immunological GvT effect and antitumor effect
of cytotoxic chemotherapy used in the pretransplant
conditioning regimen, allogeneic T-lymphocytes were
removed from the stem cell graft and were subsequently
administered at escalating doses after allo-HSCT (on +42,
+70, and +98 days). Objective tumor regression occurred
in 6 patients 28 days after allo-HSCT. Disease progression
following allo-HSCT was observed before subsequent
tumor regression in 2 patients. Tumor regressions obtained
simultaneously with the accomplishment of complete
donor T-lymphoid engraftment were associated with
the development of GvHD and abrogated after systemic
immunosuppression[32].
A study by Ueno et al. reported that patients who
developed acute GvHD after a RIC regimen had lower
relapse or progression risk than those who did not (P <
0.03). However, this did not translate into a relapse-free
survival advantage [33]. Immune manipulation such as
DLI for persistent or progressive disease were performed
in 9 out of 33 patients (27%) and led to disease response
or stable disease. Authors concluded that preclinical and
clinical studies are needed in order to facilitate targeted
adoptive immunotherapy and to explore the benefit of a
GvT effect in BC [33, 36].
3.5. GvT effect in soft tissue sarcomas
Immune-mediated effect against soft tissue sarcomas
(STS) has been shown in experimental animal models of
allo-HSCT [20, 73]. Most of the evidence comes from case
reports and small series of patients transplanted from HLAmatched siblings. Despite several reports ofthe presence of
a graft-versus-sarcoma effect, [74, 75] tumor regression
following allo-HSCT with RIC regimens has not been
reported among patients with various histologic subtypes
[76]. A retrospective study by Secondino et al. evaluated
14 adult patients with advanced STS receiving allo-HSCT
with RIC in the EBMT database. Overall, acute GvHD was
reported in 9 patients (64%). Grades 3–4 acute GvHD was
observed in 4 (28%) and grade 2 in 5 cases (36%). Chronic
GvHD occurred in 4 out of 9 evaluable patients (44%)
and was extensive in 2. Four patients experienced durable
disease stabilization following allo-HSCT [77]. A well
designed phase 2 study, enrolling patients with limited
tumor burden and slow growing tumors, may help to
define the possible role of allo-HSCT with RIC in patients
with STS in whom conventional treatments have failed.
3.6.GvT effect of haploidentical stem cell transplantation
in refractory solid tumors
Innovative allo-HSCT approaches such as haploidentical
HSCT, which takes advantage of GvT effects in order to
control disease, while minimizing the treatment related
mortality or scale of GvHD, are being studied in many
recent clinical trials [21–24]. The evidence of haploidentical
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HSCT in solid tumors are mainly limited to pediatric solid
tumors such as neuroblastoma and sarcomas [21–23].
A pilot study by Lang et al. evaluated the feasibility and
toxicity of transplantation of haploidentical T and B-cell
depleted grafts with high numbers of NK cells. Since grade
2 acute GvHD was observed in 4 patients andchronic
GvHD in 2, it was concluded that haploidentical HSCT
is feasible with low toxicity even in intensively pretreated
patients with neuroblastomas and sarcomas [21]. Llosa
et al. also reported the results of haploidentical stem cell
transplantation with RIC in 16 pediatric and adolescent, as
well as young adult patients with solid tumors. A limited
GvHD was seen in 3 patients and non-relapse mortality
in 1 patient. This approach may serve as a platform for
posttransplant strategies to prevent relapse and optimize
PFS[22].
4. The role of recipient derived immune effector cells in
the antitumor effects
The anticancer effect of RDICs was first time suggested
by Alexander et al. in 1996. They reported that
xenogeneic lymphocytes from tumor immunized sheep
reduced fibrosarcoma growth in immuno competent
rats. The observed anticancer effect was not mediated
via direct antitumor activity of donor T-cells as these
were rapidly rejected in the xenogeneic setting, rather a
“messengersignal” created by the infused xenogeneic donor
cells in directly boosted recipient’s immune reactions[78].
Ellman and Katz et al. also suggested that host ant-tumor
immunity is involved in the antitumor effect[79]. They
reported that host antitumor immunity could be achieved
even when the all ogeneic cells are already fully rejected
and continuous tumor protection had been observed in
50% of rechallenged long-term survivors of allogeneic
lymphocyte-infused animals [80]. These initial findings
suggest that a GvH reaction is a prerequisite for a hostanti tumor activity to occur in thesetting of DLI, where
RDICs are stimulated to elicit antitumor responses. In
concordance, RDICs are presented as key players in the
anticancer activity after allo-HSCT. Symons et al. reported
that the transfer of CD8+ T-cell-depleted DLI graft into
cyclophosphamide-treated A20 leukemia/lymphomabearing mice increased the survival directly through
a GvH anti-tumorreaction of donor CD4+ T-cells and
indirectly through stimulation of recipient CD8+ T-cell
antitumor immunity [81].
Recipient derived antigen presenting cells (APCs)
also play an important role during GvH reactions. In
the early postallo-HSCT period, conditioning-induced
tissue inflammation stimulates recipient APCs and they
in turn prime alloreactive donor T-cells [82, 83]. Crosspresentation of recipient antigens by donor APCs may also
occur after allo-HSCT. However, it still not clearly defined
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to what extent it occurs in human beings [83]. The role of
recipient APCs in eliciting effective anticancer responses
is very important and it is reflected in clinical studies
reporting the outcome of DLI in advanced solid tumors.
RDICs may have a principal effector role in the anticancer
effect against renal cell carcinoma (RCC), as a significant
tumor regression occurred despite a gradual decrease
in donor chimerism[84]. This observation, reported by
Harano et al., suggests that a temporary presence of donor
cells is enough to create a GvH reaction and may provide
inflammatory signals that facilitate the loss of tolerance
of recipient CD8+ T-cells to the recipient’s tumor [84].
Similarly, Omazic et al. also showed a durable remission
among patients with advanced refractory solid tumors in
the presence of donor graft rejection [37].
As the preclinical and clinical evidences suggest that
donor cells may only be needed in the initial induction
phase of a GvT effect [37, 81], the research has focused on
exploiting the potential of RDICs without increasing the
risk of GvHD. Inmouse models of leukemia, Rubio et al.
and De Somer et al. intentionally created graft rejection
via “recipient leukocyte infusion” (RLI) [85, 86]. A hostversus-graft (HvG) reaction created by RLI into mixed
chimer as triggered a reaction of RLI-derived donorreactive recipient T-cells and resulted in full donor graft
rejection and an important antileukemic response without
increasing the GvHD risk.
In summary, these findings support the initial reports
suggesting that RDICs may act as key effectors in the
anticancer effect after allo-HSCT. These results also
strongly suggest that the effective anticancer responses
mediated byRDICs are not solely through a GvHr eaction
[81, 84], but also a HvG reaction [81, 84, 87, 88].
5. Chimeric antigen receptorT-cell (CAR-T) therapy for
solid tumors
Chimeric antigen receptor modified T-cell (CAR-T)
therapy has achieved encouraging breakthroughs in the
treatment of hematological malignancies. Nevertheless,
this success has not yet been extrapolated to solid tumors
[89]. Infact, the vast majority of cancers, in particular the
more common solid cancers, including the breast, colon and
lung, failed to respond significantly to CAR-T treatment.
The suppression of T-cell function and inhibition of T-cell
localization are some formidable barriers of solid cancers
to adoptive cell transfer [90].
However, some promising results have also been
reported in some early phase studies [91]. Phase 1 studies
of GD2-specific CAR-T cells for neuroblastoma, CAR-T
cells specifically targeting HER2, EGFR and IL-13 for
glioblastoma multiforme, mesothelin-specific CAR-T
cells for advanced malignant pleural mesothelioma or
pancreatic cancer, CAR-T cells specific for epidermal

ŞAHİN and DEMİRER / Turk J Med Sci
growth factor receptor (EGFR) for advanced nonsmallcell lung cancer and cholangiocarcinoma, CEA specific
CAR-T cells for metastatic CRC have reported positive
initial results [92–99].
Despite some promising results, the ultimate success
of CAR-T therapies in solid tumors may require some
adjustments and improvements. The combination of
CAR-T cells with chemotherapy to treatmet as tatic
tumors, local delivery of CAR-T cells,using CAR-T cells
targeting two different antigens, combined therapy with
CAR-T and immune check point inhibitors and finally the
use of CAR-T as a strategy to prevent tumor recurrence and
metastasis after curative resection are current questions to
be further studied [89].
6. Tumor infiltrating T-cells in refractory solid tumors
The infiltration of the tumor tissue with T cells targeting
tumor associated antigens has been shown to be associated
with a favorable prognosis in several solid tumors. Upon
this observation ongoing studies have been investigating
the idea of extraction, ex vivo expansion with homeostatic
cytokines and reinfusion into the patients as a novel
treatment strategy [91]. Tumor infiltrating lymphocytes
(TILs) were first reported by Rosenberg et al. in 1988
and they demonstrated the antimelanoma effects of
IL-2 induced TILs [100]. The treatment with TILs and
high-dose IL-2 has proven a 34% objective response rate
[101–103]. TIL therapy has been reported to have lower
response rates in patients progressed on anti-PD-1 therapy.
However, TIL therapy remains an important treatment
strategy in refractory malignant melanoma, as durable
complete responses can still be induced after progression
on anti-PD-1 [104].
Despite the demonstration of TILs in other solid
tumors, their expansion and in vivo efficacy have not been
a great success as in melanoma [101]. However, there are
promising preliminary data with cholangiocarcinoma
and cervical cancer [105, 106] and some clinical trials in
gastrointestinal, gynecological, head and neck, breast and
lung cancers are currently ongoing [91].
TIL therapy in melanoma is an advanced therapy
medicinal product and its clinical implementation is
challenging. Thus, it has not been widely recognized. It has
been availablein the Europe since 2011 as an experimental
therapy. Reimbursement procedures and organization of
knowledge transfer could improve clinical translation of
TIL therapy [107].
7. Summary
Current evidence suggests the presence of graft-versuscancer effect in various solid tumors. Allo-HSCT with
RIC may provide some degree of response in some
refractory metastatic solid tumors, such as renal, ovarian,

breast and even colon cancers. Lower toxicity profile
and lower nonrelapse mortality rate make RIC regimens
a plausible treatment modality. To date, the results of
this treatment modality in refractory solid tumors are
associated with lower CR and PR rates with few long-term
survivors, which is similar to CAR-T Cell experiences in
refractory solid tumors. Current literature data imply that
mechanisms of GVT effect and interaction of T-cells and
their subsets with main mediators may be highly different
in solid tumors compared to hematologic malignancies.
Therefore, further studies are needed shedding light upon
these mechanisms in order to exploit this valuable effect in
refractory solid tumors.
Despite its great potential, the use of ATCT for cancer
control yet has a marginal role in the management of
patients with solid tumors. However, it has recently come
into attraction in melanoma treatment [36]. Indeed, the
extensive infrastructure needed for exploiting ATCT
effects still restrict its use to academic centers with specific
programs in the field. It should be emphasized that the
major obstacle for a wider application of ATCT to treat
human cancer is the personalized nature of the approach
[36].
Although donor T-cells are accepted as the main
mediators of the anticancer effect following allo-HSCT,
recent findings also point out a key role for RDICs. Recent
experimental studies appointed RLI as an important tool to
reinforce anticancer effects after allo-HSCT by exploiting
RDICs, both in leukemia and solid tumor models with an
advantage of lower rates of GvHD. These results supporting
the contribution of RDICs in the anticancer effect of alloHSCT are mainly observed in murine models, and the
experience in human is limited. Future clinical trials may
explore the emerging role and anticancer effects of RDICs
in patients receiving allo-HSCT.
Further studies and experience are warranted
regarding the use of haploidentical HSCT, CAR-T cell
therapies, posttransplant immunomodulatory agents
and tumor infiltrating T-cells in patients with refractory
solid tumors [89, 90, 108–114]. Future studies should
include patients with better performance status and
chemotherapy responsive disease before transplant in
order to obtain the maximal benefit from GvT effect in
solid tumors. Well-designed trials are needed for a clearcut understanding of the interactions of donor T-cells and
their subsets, mechanisms of GvT effects, which possibly
use different mechanisms in solid tumors and hematologic
malignancies, in order to optimize the efficacy of such
treatment modalities in patients with refractory solid
tumors.
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